The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy
Author
Bartalena, L.
Kahaly, G. J.
Baldeschi, L.
Dayan, C. M.
Eckstein, A.
Marcocci, C.
Marinò, M.
Vaidya, B.
Wiersinga, W. M.
Date
2021-08-27Journal
European journal of endocrinologyType
Journal ArticlePublisher
BioScientificaDOI
10.1530/eje-21-0479Rights
© European Society of Endocrinology 2021Metadata
Show full item recordAbstract
Graves' orbitopathy (GO) is the main extrathyroidal manifestation of Graves' disease (GD). Choice of treatment should be based on the assessment of clinical activity and severity of GO. Early referral to specialized centers is fundamental for most patients with GO. Risk factors include smoking, thyroid dysfunction, high serum level of thyrotropin receptor antibodies, radioactive iodine (RAI) treatment, and hypercholesterolemia. In mild and active GO, control of risk factors, local treatments, and selenium (selenium-deficient areas) are usually sufficient; if RAI treatment is selected to manage GD, low-dose oral prednisone prophylaxis is needed, especially if risk factors coexist. For both active moderate-to-severe and sight-threatening GO, antithyroid drugs are preferred when managing Graves' hyperthyroidism. In moderate-to-severe and active GO i.v. glucocorticoids are more effective and better tolerated than oral glucocorticoids. Based on current evidence and efficacy/safety profile, costs and reimbursement, drug availability, long-term effectiveness, and patient choice after extensive counseling, a combination of i.v. methylprednisolone and mycophenolate sodium is recommended as first-line treatment. A cumulative dose of 4.5 g of i.v. methylprednisolone in 12 weekly infusions is the optimal regimen. Alternatively, higher cumulative doses not exceeding 8 g can be used as monotherapy in most severe cases and constant/inconstant diplopia. Second-line treatments for moderate-to-severe and active GO include (a) the second course of i.v. methylprednisolone (7.5 g) subsequent to careful ophthalmic and biochemical evaluation, (b) oral prednisone/prednisolone combined with either cyclosporine or azathioprine; (c) orbital radiotherapy combined with oral or i.v. glucocorticoids, (d) teprotumumab; (e) rituximab and (f) tocilizumab. Sight-threatening GO is treated with several high single doses of i.v. methylprednisolone per week and, if unresponsive, with urgent orbital decompression. Rehabilitative surgery (orbital decompression, squint, and eyelid surgery) is indicated for inactive residual GO manifestations.
Citation
Eur J Endocrinol. 2021 Aug 27;185(4):G43-G67. doi: 10.1530/EJE-21-0479.Publisher URL
https://eje.bioscientifica.com/doi/10.1530/EJE-21-0479Note
This article is freely available online. Click on the 'Additional Link' above to access the full-text via the publisher's site.Collections
Related items
Showing items related by title, author, creator and subject.
-
Multi-centre randomised controlled trial of a smartphone-based event recorder alongside standard care versus standard care for patients presenting to the Emergency Department with palpitations and pre-syncope: the IPED (Investigation of Palpitations in the ED) Study.
Lloyd, Gavin (Elsevier, 2019-03)Patients with palpitations and pre-syncope commonly present to Emergency Departments (EDs) but underlying rhythm diagnosis is often not possible during the initial presentation. This trial compares the symptomatic rhythm ... -
LP or not LP, that is the question: gold standard or unnecessary procedure in subarachnoid haemorrhage?
Stewart, H.; Reuben, Adam; McDonald, J. (BMJ, 2014-09-01)OBJECTIVE: To measure the sensitivity of modern CT in patients presenting to the emergency department and evaluated for possible subarachnoid haemorrhage, with particular attention to those presenting within 12 h of ictus. ... -
Derivation and external validation of a case mix model for the standardized reporting of 30-day stroke mortality rates
Bray, B. D.; Campbell, J.; Cloud, G. C.; Hoffman, A.; James, Martin; Tyrrell, P. J.; Wolfe, C. D.; Rudd, A. G.; Intercollegiate Stroke Working Party, Group (Stroke, 2014-11-01)BACKGROUND AND PURPOSE: Case mix adjustment is required to allow valid comparison of outcomes across care providers. However, there is a lack of externally validated models suitable for use in unselected stroke admissions. ...